AU2015317351B2 - Costimulatory chimeric antigen receptor T cells targeting IL3Ra2 - Google Patents

Costimulatory chimeric antigen receptor T cells targeting IL3Ra2 Download PDF

Info

Publication number
AU2015317351B2
AU2015317351B2 AU2015317351A AU2015317351A AU2015317351B2 AU 2015317351 B2 AU2015317351 B2 AU 2015317351B2 AU 2015317351 A AU2015317351 A AU 2015317351A AU 2015317351 A AU2015317351 A AU 2015317351A AU 2015317351 B2 AU2015317351 B2 AU 2015317351B2
Authority
AU
Australia
Prior art keywords
cells
amino acid
seq
sequence
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015317351A
Other languages
English (en)
Other versions
AU2015317351A1 (en
Inventor
Christine E. BROWN
Stephen J. Forman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2015317351(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by City of Hope filed Critical City of Hope
Publication of AU2015317351A1 publication Critical patent/AU2015317351A1/en
Priority to AU2020203651A priority Critical patent/AU2020203651A1/en
Application granted granted Critical
Publication of AU2015317351B2 publication Critical patent/AU2015317351B2/en
Priority to AU2021277651A priority patent/AU2021277651A1/en
Priority to AU2024201326A priority patent/AU2024201326A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015317351A 2014-09-19 2015-09-18 Costimulatory chimeric antigen receptor T cells targeting IL3Ra2 Active AU2015317351B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020203651A AU2020203651A1 (en) 2014-09-19 2020-06-03 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2
AU2021277651A AU2021277651A1 (en) 2014-09-19 2021-11-30 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2
AU2024201326A AU2024201326A1 (en) 2014-09-19 2024-02-28 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053068P 2014-09-19 2014-09-19
US62/053,068 2014-09-19
PCT/US2015/051089 WO2016044811A1 (en) 2014-09-19 2015-09-18 COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13Rα2

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020203651A Division AU2020203651A1 (en) 2014-09-19 2020-06-03 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2

Publications (2)

Publication Number Publication Date
AU2015317351A1 AU2015317351A1 (en) 2017-04-06
AU2015317351B2 true AU2015317351B2 (en) 2020-07-02

Family

ID=55533940

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2015317351A Active AU2015317351B2 (en) 2014-09-19 2015-09-18 Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
AU2020203651A Abandoned AU2020203651A1 (en) 2014-09-19 2020-06-03 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2
AU2021277651A Abandoned AU2021277651A1 (en) 2014-09-19 2021-11-30 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2
AU2024201326A Abandoned AU2024201326A1 (en) 2014-09-19 2024-02-28 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020203651A Abandoned AU2020203651A1 (en) 2014-09-19 2020-06-03 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2
AU2021277651A Abandoned AU2021277651A1 (en) 2014-09-19 2021-11-30 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2
AU2024201326A Abandoned AU2024201326A1 (en) 2014-09-19 2024-02-28 Costimulatory Chimeric Antigen Receptor T Cells Targeting IL13Ra2

Country Status (14)

Country Link
US (3) US9914909B2 (OSRAM)
EP (4) EP3194433B1 (OSRAM)
JP (7) JP6657195B2 (OSRAM)
KR (3) KR102683584B1 (OSRAM)
CN (4) CN113789336B (OSRAM)
AU (4) AU2015317351B2 (OSRAM)
BR (3) BR122024000360A2 (OSRAM)
CA (2) CA2961654A1 (OSRAM)
DK (1) DK3200591T3 (OSRAM)
ES (2) ES2738705T3 (OSRAM)
IL (6) IL308324A (OSRAM)
MX (4) MX387135B (OSRAM)
RU (2) RU2749922C2 (OSRAM)
WO (2) WO2016044811A1 (OSRAM)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110615835A (zh) 2012-08-09 2019-12-27 利兰斯坦福初级大学董事会 选择性地操纵靶细胞中对两个或更多个共有受体多肽识别的配体的细胞反应的方法
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9657105B2 (en) 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP3049526B1 (en) 2013-09-24 2021-02-24 Medicenna Therapeutics, Inc. Interleukin-4 receptor-binding fusion proteins and uses thereof
AU2015317351B2 (en) * 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2
DK3298033T4 (da) 2015-05-18 2023-10-02 Tcr2 Therapeutics Inc Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
WO2017015490A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
AU2016301932B2 (en) * 2015-08-05 2020-02-27 CellabMED Inc. Chimeric antigen receptor, and T cells in which chimeric antigen receptor is expressed
CN109328074A (zh) 2016-04-01 2019-02-12 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
CA3177398A1 (en) 2016-04-01 2017-10-05 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
AR108067A1 (es) * 2016-04-01 2018-07-11 Kite Pharma Inc Moléculas de unión y métodos de uso de los mismos
JP2019516352A (ja) * 2016-04-01 2019-06-20 アムジエン・インコーポレーテツド Ｆｌｔ３に対するキメラ受容体及びその使用方法
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
AU2017276706B2 (en) * 2016-06-07 2024-08-15 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Chimeric antigen receptor and CAR-T cells that bind BCMA
AU2017279548B2 (en) * 2016-06-08 2024-08-08 Precigen, Inc. CD33 specific chimeric antigen receptors
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
CN110177558B (zh) * 2016-09-16 2025-02-28 贝勒医学院 用于病毒特异性t细胞的活化和扩增的平台
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
WO2018106972A1 (en) * 2016-12-07 2018-06-14 La Jolla Institute For Allergy And Immunology Compositions for cancer treatment and methods and uses for cancer treatment and prognosis
US12473343B2 (en) 2017-01-10 2025-11-18 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CN108395481B (zh) * 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
US12083148B2 (en) * 2017-02-22 2024-09-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. IL13Ra2-binding chimeric antigen receptors
US11850262B2 (en) 2017-02-28 2023-12-26 Purdue Research Foundation Compositions and methods for CAR T cell therapy
US20210122831A1 (en) * 2017-03-27 2021-04-29 Noile-Immune Biotech, Inc. Chimeric antigen receptor
JP7505885B2 (ja) 2017-04-14 2024-06-25 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的にするキメラ抗原受容体ｔ細胞
CN110753555A (zh) 2017-04-19 2020-02-04 得克萨斯州大学系统董事会 表达工程化抗原受体的免疫细胞
CN107267555B (zh) * 2017-05-27 2020-03-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用
EP3664841A1 (en) * 2017-08-11 2020-06-17 City of Hope Oncolytic virus expressing a car t cell target and uses thereof
EP3694558B1 (en) 2017-10-10 2024-04-10 Medicenna Therapeutics Inc. Il-4-fusion formulations for treatment of central nervous system (cns) tumors
AU2018362014A1 (en) * 2017-11-03 2020-05-28 Sorrento Therapeutics, Inc. CD38-directed chimeric antigen receptor constructs
US20200345823A1 (en) * 2017-11-07 2020-11-05 Xiuli Wang Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car
CN109971712B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN120154716A (zh) 2018-01-22 2025-06-17 恩多塞特公司 Car t细胞的使用方法
WO2019148006A1 (en) * 2018-01-26 2019-08-01 City Of Hope Chimeric antigen receptors and methods for reducing off target toxicity
JP7774961B2 (ja) 2018-02-06 2025-11-25 シアトル チルドレンズ ホスピタル ディー／ビー／エイ シアトル チルドレンズ リサーチ インスティテュート フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
JP2021512635A (ja) * 2018-02-12 2021-05-20 ザ ジェネラル ホスピタル コーポレイション 腫瘍微小環境を標的とするキメラ抗原受容体
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
CA3093791A1 (en) * 2018-03-14 2019-09-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy
JP7438123B2 (ja) * 2018-03-14 2024-02-26 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 腫瘍特異的Ｔ細胞免疫療法用のＩＬ－１３受容体α２（ＩＬ１３Ｒα２）標的キメラ抗原受容体
WO2019195586A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
AU2019249221A1 (en) 2018-04-06 2020-10-22 The Regents Of The University Of California Methods of treating glioblastomas
BR112020023489A8 (pt) * 2018-05-21 2022-12-20 Biosceptre Uk Ltd Receptores de antígenos quiméricos com domínios de ligação modificados e usos dos mesmos
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
US20210214410A1 (en) * 2018-06-01 2021-07-15 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
EP3813951B1 (en) 2018-06-29 2025-11-12 City of Hope Cd6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
KR102897600B1 (ko) * 2018-08-10 2025-12-09 주식회사 유틸렉스 암항원 특이적 세포독성 t세포
KR20210090220A (ko) * 2018-11-06 2021-07-19 워싱턴 유니버시티 키메라 항원 수용체 기억-유사 (carml) nk 세포 및 이를 만들고, 이용하는 방법
US20230065784A1 (en) 2019-03-21 2023-03-02 City Of Hope Composition and method for reducing expression of checkpoint inhibitors in t cells expressing a car or ctl
WO2020205751A1 (en) 2019-03-29 2020-10-08 City Of Hope Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
WO2020243007A1 (en) * 2019-05-24 2020-12-03 City Of Hope Ccr4 targeted chimeric antigen receptor modified t cells for treatment of ccr4 positive malignancies
WO2021004400A1 (zh) * 2019-07-06 2021-01-14 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
CN112204135A (zh) * 2019-07-06 2021-01-08 苏州克睿基因生物科技有限公司 一种表达cd3抗体受体复合物的免疫细胞及其用途
WO2021016585A1 (en) * 2019-07-24 2021-01-28 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
EP3769816A1 (en) * 2019-07-25 2021-01-27 Ospedale Pediatrico Bambino Gesù Car-cd123 vector and uses thereof
EP4084808A1 (en) 2019-12-30 2022-11-09 City of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
JP2023512250A (ja) * 2020-01-31 2023-03-24 シティ・オブ・ホープ ＩＬ１３Ｒα２陽性悪性腫瘍の治療のための標的キメラ抗原受容体修飾Ｔ細胞
US20230374085A1 (en) * 2020-03-11 2023-11-23 City Of Hope Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment
EP4118106A1 (en) * 2020-03-12 2023-01-18 City of Hope TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF IL13Ralpha2 POSITIVE MALIGNANCIES
BR112022021551A2 (pt) 2020-04-28 2023-01-03 Lyell Immunopharma Inc Métodos para cultivar células
US20230220419A1 (en) * 2020-05-27 2023-07-13 The Medical College Of Wisconsin, Inc. Improved Lentiviral Vector Transfer Plasmid and Methods of Use
GB202011993D0 (en) 2020-07-31 2020-09-16 Adc Therapeutics Sa ANTI-IL 13Ra2 antibodies
CN116322717A (zh) * 2020-08-11 2023-06-23 耶达研究及发展有限公司 否决car-t细胞
CA3194747A1 (en) * 2020-09-10 2022-03-17 Mustang Bio, Inc. Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer
WO2022098797A1 (en) * 2020-11-04 2022-05-12 Fred Hutchinson Cancer Research Center Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy
WO2022109498A1 (en) 2020-11-23 2022-05-27 City Of Hope Engineered t cells for expression of chimeric anitgen receptors
KR20230118887A (ko) 2020-12-03 2023-08-14 센츄리 쎄라퓨틱스 인코포레이티드 유전자 조작 세포 및 이의 용도
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
CN118146395A (zh) * 2021-02-08 2024-06-07 浙江大学 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体
WO2022182891A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
KR20230175198A (ko) * 2021-03-18 2023-12-29 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 IL13Rα2를 표적으로 하는 DNA 암호화 이중특이적 항체 및 이를 암 치료에 사용하는 방법
US20240366662A1 (en) 2021-03-30 2024-11-07 City Of Hope Car t cell therapy and ifn gamma
US20230190799A1 (en) * 2021-07-21 2023-06-22 City Of Hope Chimeric antigen receptor t cells targeting cea and anti-cea-il2 immunocytokines for cancer therapy
CN113621077B (zh) * 2021-09-02 2023-01-31 山东大学 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
EP4176895A1 (en) * 2021-11-08 2023-05-10 AvenCell Europe GmbH Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor
WO2023130462A1 (zh) * 2022-01-10 2023-07-13 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的嵌合抗原受体及其用途
CN115960257B (zh) * 2022-09-29 2023-10-27 卡瑞济(北京)生命科技有限公司 靶向IL13Rα2的经优化的嵌合抗原受体及其用途
EP4588939A1 (en) 2024-01-16 2025-07-23 Universitat de Barcelona Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025177A1 (en) * 2008-08-26 2010-03-04 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100246529B1 (ko) 1990-12-14 2000-04-01 스티븐 에이. 서윈. 엠.디. 수용체 관련된 신호 변환 경로를 위한 키메라 사슬
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
RU2167676C2 (ru) * 1995-02-24 2001-05-27 Дзе Дженерал Хоспитал Корпорейшн Перенаправление клеточного иммунитета посредством химерных рецепторов
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US6576232B1 (en) 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
EP1591128A1 (en) 1998-07-30 2005-11-02 The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health Thymosin beta 4 promotes wound repair
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2001034645A2 (en) * 1999-11-11 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Mutated il-13 molecules and their uses
US7560280B2 (en) 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US7514537B2 (en) 2001-04-30 2009-04-07 City Of Hope Chimeric immunoreceptor useful in treating human gliomas
US20030171546A1 (en) 2001-04-30 2003-09-11 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US11278594B2 (en) * 2001-04-30 2022-03-22 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US20090257994A1 (en) * 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1501226B1 (en) 2003-07-24 2007-09-19 Matsushita Electric Industrial Co., Ltd. Method, encoder and communication device for encoding parallel concatenated data
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7754441B2 (en) * 2003-11-17 2010-07-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DE102004043271A1 (de) * 2004-09-07 2006-03-09 Linde Ag Verfahren zur Synthese von Zirkoniumcarboxylaten
PT1814580T (pt) * 2004-11-24 2016-11-11 Hutchinson Fred Cancer Res Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais
US20080293070A1 (en) * 2005-12-21 2008-11-27 Rafick-Pierre Sekaly Markers for Memory T Cells and Uses Thereof
CN101346463B (zh) * 2005-12-21 2012-06-13 江苏太瑞生诺生物医药科技有限公司 用于癌患者免疫治疗的瘤反应性t-淋巴细胞扩增的改善方法
SI2126054T1 (sl) 2007-01-31 2016-12-30 Yeda Research And Development Company Limited Preusmerjanje, genetsko spremenjene T regulatorne celice in njih uporaba v zatiranju avtoimunske in vnetne bolezni
CA2700714C (en) * 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
CN102939303A (zh) * 2009-12-22 2013-02-20 诺瓦提斯公司 四价cd47-抗体恒定区融合蛋白用于治疗
GB2481983A (en) * 2010-07-12 2012-01-18 Hart Fenton & Co Ltd A ship including a gas tank room
AU2011292248B2 (en) * 2010-08-18 2014-07-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of identifying central memory T cells and obtaining antigen-specific T cell populations
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX359513B (es) * 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res Metodo y composiciones para inmunoterapia celular.
KR20160044598A (ko) * 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
EP2532740A1 (en) * 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP2814846B1 (en) * 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
IL293944A (en) * 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
CN107074957B (zh) * 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
AU2015317351B2 (en) 2014-09-19 2020-07-02 City Of Hope Costimulatory chimeric antigen receptor T cells targeting IL3Ra2

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010025177A1 (en) * 2008-08-26 2010-03-04 City Of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Kong, S. et al., Clinical Cancer Research, 2012, 18(21), pp. 5949-5960. *

Also Published As

Publication number Publication date
CN107002084A (zh) 2017-08-01
KR20230169455A (ko) 2023-12-15
WO2016044811A1 (en) 2016-03-24
JP6657195B2 (ja) 2020-03-04
JP6711819B2 (ja) 2020-06-17
IL292650B2 (en) 2024-04-01
WO2016044853A8 (en) 2017-04-06
EP3200591B2 (en) 2024-09-25
IL280576B (en) 2022-06-01
EP3200591A4 (en) 2018-04-04
BR112017005631A2 (pt) 2018-06-26
CA2961654A1 (en) 2016-03-24
BR112017005630A2 (pt) 2018-06-26
AU2020203651A1 (en) 2020-06-25
IL292650A (en) 2022-07-01
RU2017111300A (ru) 2018-10-19
MX2017003557A (es) 2017-10-12
JP6986190B2 (ja) 2021-12-22
RU2749922C2 (ru) 2021-06-21
WO2016044853A1 (en) 2016-03-24
IL251196B (en) 2021-02-28
US9914909B2 (en) 2018-03-13
EP3194433B1 (en) 2019-05-22
IL308324A (en) 2024-01-01
IL280576A (en) 2021-03-25
AU2015317351A1 (en) 2017-04-06
MX387135B (es) 2025-03-18
EP3200591A1 (en) 2017-08-09
CN113789336A (zh) 2021-12-14
RU2017111298A3 (OSRAM) 2019-03-13
US10676717B2 (en) 2020-06-09
EP3194433A1 (en) 2017-07-26
JP2017534262A (ja) 2017-11-24
CN113637640A (zh) 2021-11-12
HK1247046A1 (zh) 2018-09-21
AU2024201326A1 (en) 2024-04-11
MX383042B (es) 2025-03-13
JP7216045B2 (ja) 2023-01-31
KR102683584B1 (ko) 2024-07-10
BR122024000360A2 (pt) 2024-02-27
JP2020156494A (ja) 2020-10-01
DK3200591T3 (da) 2021-06-21
ES2738705T3 (es) 2020-01-24
RU2017111300A3 (OSRAM) 2019-09-04
KR102610715B1 (ko) 2023-12-08
US20180265844A1 (en) 2018-09-20
IL251188A0 (en) 2017-05-29
KR20170057351A (ko) 2017-05-24
BR112017005630B1 (pt) 2023-12-12
US20160340649A1 (en) 2016-11-24
EP3916084A1 (en) 2021-12-01
IL292828A (en) 2022-07-01
MX2021006400A (es) 2021-07-15
CN107404881A (zh) 2017-11-28
IL292650B1 (en) 2023-12-01
CN107404881B (zh) 2021-07-09
MX2021012720A (es) 2022-01-06
AU2021277651A1 (en) 2021-12-23
EP3587446A1 (en) 2020-01-01
JP2022017333A (ja) 2022-01-25
KR20170054509A (ko) 2017-05-17
EP3200591B1 (en) 2021-03-31
IL251196A0 (en) 2017-05-29
CA2961676A1 (en) 2016-03-24
CN107002084B (zh) 2021-09-10
CN113789336B (zh) 2025-12-16
RU2763523C2 (ru) 2021-12-30
ES2876235T5 (en) 2025-02-12
JP2017529081A (ja) 2017-10-05
JP7171871B2 (ja) 2022-11-15
JP2023052506A (ja) 2023-04-11
JP2023014100A (ja) 2023-01-26
RU2017111298A (ru) 2018-10-19
ES2876235T3 (es) 2021-11-12
NZ730208A (en) 2024-03-22
US20200318069A1 (en) 2020-10-08
MX2017003596A (es) 2017-10-20
JP2020100626A (ja) 2020-07-02
IL251188B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
US10676717B2 (en) Costimulatory chimeric antigen receptor T cells targeting IL13Rα2
AU2021200122B2 (en) CS1 Targeted Chimeric Antigen Receptor-Modified T Cells
US20230348617A1 (en) Chimeric antigen receptors targeted to psca
EP3362470B1 (en) Chimeric antigen receptors containing a chlorotoxin domain
AU2020203550A1 (en) Central Memory T Cells for Adoptive T Cell Therapy
HK40020210A (en) Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
HK40063401A (en) Chimeric antigen receptors containing a chlorotoxin domain
HK40036816A (en) Chimeric antigen receptors targeted to psca

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)